Fabrazyme Genzyme Corp - Treatment for Fabry Disease
Fabrazyme is a recombinant form of human alpha-galactosidase A, administered intravenously for the treatment of Fabry Disease.Posted: April 2003
 |
 |
Related Fabrazyme Information
Recently Approved
- Mekinist Mekinist (trametinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or...
- Tafinlar Tafinlar (dabrafenib) is a kinase inhibitor indicated for the treatment of patients with unresectable or...
- Xofigo Xofigo (radium 223 dichloride) is an alpha particle-emitting radioactive therapeutic agent indicated for...
- Nymalize Nymalize (nimodipine) is a calcium channel blocker indicated to improve neurological outcome following...
- Breo Ellipta Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid / long-acting beta2 agonist...
Get Updates by Email
Email me:
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated May 17th, 2013), Cerner Multum™ (updated June 18th, 2013), Wolters Kluwer™ (updated June 17th, 2013) and others. To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2013 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here